Le Lézard
Classified in: Science and technology, Business
Subject: ATY

Updated Notice on Lawsuit Against Monkey Capital ICO and Daniel Harrison



CORAL SPRINGS, Fla., March 8, 2018 /PRNewswire/ -- Silver Miller (www.SilverMillerLaw.com) -- the leading cryptocurrency investor law firm in the country, with actions currently pending against the Coinbase, Kraken, BitConnect, and Cryptsy exchanges as well as the first federally-filed class action lawsuit against heavily-embattled Tezos and its billion dollar July 2017 Initial Coin Offering (ICO) -- is currencly prosecuting a civil action on behalf of a group of individuals who contributed bitcoin and other cryptocurrency to the scheduled-but-cancelled 2017 Monkey Capital ICO.  The lawsuit was filed in the United States District Court for the Southern District of Florida and is captioned Hodges, et al. v. Monkey Capital LLC, et al., Case No. 9:17-cv-81370-DMM (the "Lawsuit").  Although the Lawsuit was originally filed as a putative class action, the case has since limited its reach to merely the claimants named in the Lawsuit, who seek the return of the millions of dollars' worth of cryptocurrency they invested with Monkey Capital.  A copy of the Amended Complaint filed in the Lawsuit can be seen here:

2018-3-7 -- DE 28 - AMENDED COMPLAINT

As alleged in the Amended Complaint, Monkey Capital LLC, Monkey Capital Inc., and the companies' founder and principal (Daniel Harrison) fraudulently promoted an ICO and engaged in an unregistered offering and sale of securities that violated numerous state and federal securities laws.  The Lawsuit pleads that the Court rescind all investments in Monkey Capital; return to the investors their cryptocurrency; require Monkey Capital to account for all funds raised from investors; and adjudicate that Monkey Capital and Mr. Harrison violated multiple securities laws when they promoted and abruptly abandoned the unregistered, pre-functional ICO.

If you invested in Monkey Capital or another one of Daniel Harrison's cryptocurrency offerings such as Futereum and you have any questions concerning your rights or interests as they relate to your investment, or if you wish to participate in the Lawsuit, you are encouraged to contact David C. Silver of Silver Miller at (954) 516-6000 or DSilver@SilverMillerLaw.com to discuss your matter.

Contact:
David C. Silver
Silver Miller ? Managing Partner
Florida 954-516-6000
Maryland 240-516-6000
Washington, D.C. 202-852-6000
E-Mail: DSilver@SilverMillerLaw.com

 

SOURCE Silver Miller


These press releases may also interest you

at 17:00
SCOTTSDALE, Ariz., June 23, 2018 /PRNewswire-PRWeb/ -- Impact Horsepower, led by heralded Internet marketer Dante McClain, is disrupting the traditional fitness business with an innovative lead generation solution. The company's selling point ? and...

at 13:30
One Drop, a leader in the development of digital therapeutics solutions for people with diabetes, today announced the launch of Blood Glucose Prediction and Automated Decision Support. Through these new features, the One Drop | Mobile app will...

at 10:00
LAS VEGAS, June 23, 2018 /PRNewswire-PRWeb/ -- Wyndham Hotel Group, Amazon, United Airlines, Skyscanner, Google, Booking.com, Marriott, Accor Hotels, Twitter, Cosmopolitan Las Vegas, Winding Tree and more are just a handful of experts confirmed to...

at 10:00
SAN FRANCISCO, June 23, 2018 /PRNewswire-PRWeb/ -- GNation was honored to attend the 24th Electronic Entertainment Expo, E3 2018, from June 12th to June 14th in Los Angeles. E3 is the world's premiere trade show for computer and video games and...

at 10:00
Boehringer Ingelheim and Eli Lilly and Company today announced findings from two new analyses of the landmark EMPA-REG OUTCOME® trial, presented at the 78th American Diabetes Association (ADA) Scientific Sessions®. Results include a post-hoc...

at 08:00
Amgen  today announced new data that show Repatha® (evolocumab) significantly reduced low-density lipoprotein cholesterol (LDL-C) and non-high density lipoprotein cholesterol (non-HDL-C) in patients with Type 2 diabetes and hypercholesterolemia or...




News published on 8 march 2018 at 19:31 and distributed by: